{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:53:19Z","timestamp":1793641999712,"version":"4.5.1"},"reference-count":233,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of clonal plasma cells in the bone marrow (BM). It is known that early genetic mutations in post-germinal center B\/plasma cells are the cause of myelomagenesis. The acquisition of additional chromosomal abnormalities and distinct mutations further promote the outgrowth of malignant plasma cell populations that are resistant to conventional treatments, finally resulting in relapsed and therapy-refractory terminal stages of MM. In addition, myeloma cells are supported by autocrine signaling pathways and the tumor microenvironment (TME), which consists of diverse cell types such as stromal cells, immune cells, and components of the extracellular matrix. The TME provides essential signals and stimuli that induce proliferation and\/or prevent apoptosis. In particular, the molecular pathways by which MM cells interact with the TME are crucial for the development of MM. To generate successful therapies and prevent MM recurrence, a thorough understanding of the molecular mechanisms that drive MM progression and therapy resistance is essential. In this review, we summarize key mechanisms that promote myelomagenesis and drive the clonal expansion in the course of MM progression such as autocrine signaling cascades, as well as direct and indirect interactions between the TME and malignant plasma cells. In addition, we highlight drug-resistance mechanisms and emerging therapies that are currently tested in clinical trials to overcome therapy-refractory MM stages.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1243997","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T17:04:55Z","timestamp":1694019895000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Molecular and immunological mechanisms of clonal evolution in multiple myeloma"],"prefix":"10.3389","volume":"14","author":[{"given":"Stefan","family":"Forster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Radpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Ochsenbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00117-021-00926-z","article-title":"Multiples Myelom aus Sicht der Pathologie","volume":"62","author":"Vogelsberg","year":"2022","journal-title":"Radiologe"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"B3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"101459","DOI":"10.1016\/j.tranon.2022.101459","article-title":"Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies","volume":"22","author":"Atilla","year":"2022","journal-title":"Transl Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01051-x","article-title":"Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)","volume":"34","author":"Ho","year":"2020","journal-title":"Leukemia"},{"key":"B8","first-page":"23","volume-title":"Genomic Aberrations in Multiple Myeloma BT - Plasma Cell Dyscrasias","author":"Manier","year":"2016"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.934008","article-title":"Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation","volume":"12","author":"Diamantidis","year":"2022","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005885","article-title":"Progression signature underlies clonal evolution and dissemination of multiple myeloma","volume":"137","author":"Shen","year":"2021","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1038\/s41467-022-32145-y","article-title":"The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states","volume":"13","author":"Rasche","year":"2022","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.941437","article-title":"Molecular impact of the tumor microenvironment on multiple myeloma dissemination and extramedullary disease","volume":"12","author":"Forster","year":"2022","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.1.100","article-title":"In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment","volume":"91","author":"Kim","year":"1998","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1182\/blood-2009-01-202606","article-title":"The leukemic stem cell niche: current concepts and therapeutic opportunities","volume":"114","author":"Lane","year":"2009","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/cancers12040988","article-title":"Challenges for immunotherapy in multiple myeloma: bone marrow microenvironment-mediated immune suppression and immune resistance","author":"Holthof","year":"2020","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.semcancer.2018.06.006","article-title":"Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis","volume":"53","author":"Marquardt","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B21","article-title":"The potential role of CD44 and CD133 in colorectal stem cell cancer","volume":"14","author":"Abdou Hassan","year":"2022","journal-title":"Cureus"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.01.012","article-title":"Lung cancer stem cells: The root of resistance","volume":"372","author":"MacDonagh","year":"2016","journal-title":"Cancer Lett"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2030","article-title":"Identification of pancreatic cancer stem cells","volume":"67","author":"Li","year":"2007","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4252\/wjsc.v9.i10.169","article-title":"Tracing and targeting cancer stem cells: New venture for personalized molecular cancer therapy","volume":"9","author":"Radpour","year":"2017","journal-title":"World J Stem Cells"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.569017","article-title":"Molecular immunotherapy: promising approach to treat metastatic colorectal cancer by targeting resistant cancer cells or cancer stem cells","volume":"10","author":"Forster","year":"2020","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.138826","article-title":"The myeloma stem cell concept, revisited: from phenomenology to operational terms","volume":"101","author":"Johnsen","year":"2016","journal-title":"Haematologica"},{"key":"B28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1756-8722-6-91","article-title":"Fact or fiction - identifying the elusive multiple myeloma stem cell","volume":"6","author":"Kellner","year":"2013","journal-title":"J Hematol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001655157","article-title":"In multiple myeloma clonotypic CD38\u200a\u2013\u200a\/CD19\u200a+\u200a\/CD27\u200a+\u200a Memory B cells recirculate through bone marrow, peripheral blood and lymph nodes","volume":"45","author":"Rasmussen","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(01)00788-3","article-title":"Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD\/SCID mice","volume":"30","author":"Pilarski","year":"2002","journal-title":"Exp Hematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1145","article-title":"Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival","volume":"4","author":"Reghunathan","year":"2013","journal-title":"Oncotarget"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.140","article-title":"CD19\u2013CD45low\/\u2013CD38high\/CD138+ plasma cells enrich for human tumorigenic myeloma cells","volume":"26","author":"Kim","year":"2012","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.10.3576.422k01_3576_3582","article-title":"The proliferative potential of myeloma plasma cells manifest in the SCID-hu host","volume":"94","author":"Yaccoby","year":"1999","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0519-4","article-title":"Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination","volume":"34","author":"Akhmetzyanova","year":"2020","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.2134","article-title":"Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells","volume":"43","author":"Kawano","year":"2013","journal-title":"Int J Oncol"},{"key":"B38","first-page":"9.18.1","article-title":"Stem cell identification and sorting using the Hoechst 33342 Side Population (SP)","volume":"34","author":"Goodell","year":"2005","journal-title":"Curr Protoc Cytom"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802272676","article-title":"Presence of Hoechst low side populations in multiple myeloma","volume":"49","author":"Loh","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3802","article-title":"MicroRNA-451 regulates stemness of side population cells via PI3K\/Akt\/mTOR signaling pathway in multiple myeloma","volume":"6","author":"Du","year":"2015","journal-title":"Oncotarget"},{"key":"B41","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/0008-5472.CAN-14-2362","article-title":"Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma","volume":"75","author":"Yang","year":"2015","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2254","article-title":"Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells","volume":"103","author":"Jundt","year":"2004","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.93","article-title":"URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription","volume":"5","author":"Fan","year":"2014","journal-title":"Cell Death Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0305855101","article-title":"Illegitimate WNT signaling promotes proliferation of multiple myeloma cells","volume":"101","author":"Derksen","year":"2004","journal-title":"Proc Natl Acad Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-797050","article-title":"Syndecan-1 promotes Wnt\/\u03b2-catenin signaling in multiple myeloma by presenting Wnts and R-spondins","volume":"131","author":"Ren","year":"2018","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0404-1","article-title":"Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options","volume":"33","author":"van Andel","year":"2019","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-368142","article-title":"Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma","volume":"120","author":"Blotta","year":"2012","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.20517\/2394-4722.2021.35","article-title":"The multifunctional role of Notch signaling in multiple myeloma","volume":"7","author":"Sabol","year":"2021","journal-title":"J Cancer Metastasis Treat"},{"key":"B49","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41419-022-04556-8","article-title":"ALCAM regulates multiple myeloma chemoresistant side population","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611682104","article-title":"Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma","volume":"104","author":"Peacock","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004695","article-title":"ALCAM-EGFR interaction regulates myelomagenesis","volume":"5","author":"Luo","year":"2021","journal-title":"Blood Adv"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27190","article-title":"The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression","volume":"10","author":"Gilad","year":"2019","journal-title":"Oncotarget"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3892\/or.2019.6968","article-title":"The PI3K\/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma","volume":"41","author":"Wang","year":"2019","journal-title":"Oncol Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03261-0","article-title":"CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence","volume":"115","author":"Serizawa","year":"2022","journal-title":"Int J Hematol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz159","article-title":"Identification and characterization of tumor-initiating cells in multiple myeloma","volume":"112","author":"Gao","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405977","article-title":"Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides","volume":"120","author":"Egan","year":"2012","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.2.674.bloodjournal882674","article-title":"Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines","volume":"88","author":"Chesi","year":"1996","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.9.3025","article-title":"The t(4;14) translocation in myeloma dysregulates both FGFR3and a novel gene, MMSET, resulting in igH\/MMSET hybrid transcripts","volume":"92","author":"Chesi","year":"1998","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"crossref","DOI":"10.1038\/ng0797-260","article-title":"Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3","volume":"16","author":"Chesi","year":"1997","journal-title":"Nat Genet"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.12.4457.412k48_4457_4463","article-title":"Frequent Dysregulation of the c-maf Proto-Oncogene at 16q23 by Translocation to an Ig Locus in Multiple Myeloma","volume":"91","author":"Chesi","year":"1998","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204641","article-title":"Chromosome translocations in multiple myeloma","volume":"20","author":"Bergsagel","year":"2001","journal-title":"Oncogene"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2229","article-title":"Hypodiploidy is a major prognostic factor in multiple myeloma","volume":"98","author":"Smadja","year":"2001","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12943-022-01648-z","article-title":"Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming","volume":"21","author":"Liang","year":"2022","journal-title":"Mol Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"101472","DOI":"10.1016\/j.tranon.2022.101472","article-title":"Correlation of changes in subclonal architecture with progression in the MMRF CoMMpass study","volume":"23","author":"Kaur","year":"2022","journal-title":"Transl Oncol"},{"key":"B68","article-title":"Branching clonal evolution patterns predominate mutational landscape in multiple myeloma","volume":"11","author":"Farswan","year":"2021","journal-title":"Am J Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.3390\/biomedicines10071674","article-title":"Tracking clonal evolution of multiple myeloma using targeted next-generation DNA sequencing","volume":"10","author":"Salomon-Perzy\u0144ski","year":"2022","journal-title":"Biomedicines"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0206-x","article-title":"Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterised by clonal stability","volume":"33","author":"Dutta","year":"2019","journal-title":"Leukemia"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e159924","DOI":"10.1172\/jci.insight.159924","article-title":"Heterogeneity of B cell lymphopoiesis in patients with preMalignant and active myeloma","volume":"8","author":"Jakubikova","year":"2023","journal-title":"JCI Insight"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01597-y","article-title":"Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence","volume":"36","author":"Misund","year":"2022","journal-title":"Leukemia"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017094","article-title":"High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma","volume":"141","author":"Samur","year":"2023","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","article-title":"The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma","volume":"132","author":"Rasche","year":"2018","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2217","article-title":"Intratumor heterogeneity: evolution through space and time","volume":"72","author":"Swanton","year":"2012","journal-title":"Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0115","article-title":"HIF-2\u03b1 Promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12\/CXCR4 and CCR1","volume":"77","author":"Vandyke","year":"2017","journal-title":"Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-380410","article-title":"Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24919","article-title":"Hypoxia-inducible factor-2 alpha up-regulates CD70 under hypoxia and enhances anchorage-independent growth and aggressiveness in cancer cells","volume":"9","author":"Kitajima","year":"2018","journal-title":"Oncotarget"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02725-3","article-title":"A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration","volume":"476","author":"Sch\u00fcrch","year":"2020","journal-title":"Virchows Arch"},{"key":"B81","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12185-009-0459-2","article-title":"Methylation status of nine tumor suppressor genes in multiple myeloma","volume":"91","author":"Braggio","year":"2010","journal-title":"Int J Hematol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2007","article-title":"SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak\/STAT pathway","volume":"103","author":"Chim","year":"2004","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-017-0492-1","article-title":"Role of epigenetics-microRNA axis in drug resistance of multiple myeloma","volume":"10","author":"Rastgoo","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2048-5","article-title":"Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma","volume":"104","author":"Furukawa","year":"2016","journal-title":"Int J Hematol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1172\/JCI149526","article-title":"Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t(4;14) translocation","volume":"132","author":"Wang","year":"2022","journal-title":"J Clin Invest"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","volume":"10","author":"Barwick","year":"2019","journal-title":"Nat Commun"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.3390\/cancers14112597","article-title":"Epigenetic crosstalk between Malignant plasma cells and the tumour microenvironment in multiple myeloma","volume":"14","author":"Allegra","year":"2022","journal-title":"Cancers"},{"key":"B88","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.3390\/cancers13164069","article-title":"Investigating the interplay between myeloma cells and bone marrow stromal cells in the development of drug resistance: dissecting the role of epigenetic modifications","volume":"13","author":"Sch\u00fctt","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B89","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat Commun"},{"key":"B90","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41467-020-20715-x","article-title":"Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease","volume":"12","author":"Garcia-Gomez","year":"2021","journal-title":"Nat Commun"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e019169","DOI":"10.1161\/JAHA.120.019169","article-title":"Autocrine signaling in cardiac remodeling: A rich source of therapeutic targets","volume":"10","author":"Segers","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.221176","article-title":"IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification","volume":"105","author":"Teoh","year":"2020","journal-title":"Haematologica"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.01.002","article-title":"Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation","volume":"17","author":"Kim","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B94","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3892\/ol.2020.12202","article-title":"miR\u2212451a suppression of IL\u22126R can inhibit proliferation and increase apoptosis through the JAK2\/STAT3 pathway in multiple myeloma","volume":"20","author":"Zhong","year":"2020","journal-title":"Oncol Lett"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.2.483","article-title":"Autocrine interleukin-6 production and highly Malignant multiple myeloma: relation with resistance to drug-induced apoptosis","volume":"97","author":"Frassanito","year":"2001","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","first-page":"106785","DOI":"10.1016\/j.leukres.2022.106785","article-title":"MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner","volume":"114","author":"Liu","year":"2022","journal-title":"Leuk Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-0343","article-title":"IL6 promotes a STAT3-PRL3 feedforward loop via SHP2 repression in multiple myeloma","volume":"79","author":"Chong","year":"2019","journal-title":"Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/332083a0","article-title":"Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas","volume":"332","author":"Kawano","year":"1988","journal-title":"Nature"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.7.1915.1915","article-title":"Response patterns of purified myeloma cells to hematopoietic growth factors","volume":"73","author":"Anderson","year":"1989","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.07.006","article-title":"Revisiting IL-6 antagonism in multiple myeloma","volume":"105","author":"Matthes","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1048","article-title":"Interleukin-6\u2013dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family\u2013independent survival pathway closely associated with Stat3 activation","volume":"103","author":"Brocke-Heidrich","year":"2004","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0694","article-title":"Alterations in the transcriptional programs of myeloma cells and the microenvironment during extramedullary progression affect proliferation and immune evasion","volume":"26","author":"Ryu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.4","article-title":"Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial","volume":"6","author":"Shah","year":"2016","journal-title":"Blood Cancer J"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.4","article-title":"Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma","volume":"25","author":"Moreau","year":"2011","journal-title":"Leukemia"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02630","article-title":"Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH trial (EAY131) subprotocol W","volume":"38","author":"Chae","year":"2020","journal-title":"J Clin Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0273","article-title":"Safety, efficacy, and biomarker results from a phase Ib study of the anti-DKK1 antibody DKN-01 in combination with pembrolizumab in advanced esophagogastric cancers","volume":"20","author":"Klempner","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B107","doi-asserted-by":"publisher","first-page":"8068","DOI":"10.1200\/jco.2014.32.15_suppl.8068","article-title":"A phase 1 study evaluating the safety and efficacy of DKN-01, an investigational monoclonal antibody (Mab) in patients (pts) with advanced non-small cell lung cancer","volume":"32","author":"Edenfield","year":"2014","journal-title":"J Clin Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14483","article-title":"Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma","volume":"176","author":"Raje","year":"2017","journal-title":"Br J Haematol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1200\/JCO.2019.37.15_suppl.8012","article-title":"Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma","volume":"37","author":"Bensinger","year":"2019","journal-title":"J Clin Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.ekir.2022.01.121","article-title":"POS-109 interim results of phase 1 and 2 trials to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of BION-1301 in patients with IgA nephropathy","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27745","article-title":"Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma","volume":"119","author":"White","year":"2013","journal-title":"Cancer"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3090","article-title":"A phase I dose-escalation study of antibody BI-505 in relapsed\/refractory multiple myeloma","volume":"21","author":"Hansson","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B113","article-title":"CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity","volume":"90","author":"Bataille","year":"2005","journal-title":"Haematologica"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.18","article-title":"Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells","volume":"3","author":"Chiron","year":"2013","journal-title":"Blood Cancer J"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1618650114","article-title":"Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins","volume":"114","author":"van Andel","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.07.010","article-title":"Inhibition of the tumour necrosis factor-alpha autocrine loop enhances the sensitivity of multiple myeloma cells to anticancer drugs","volume":"49","author":"Tsubaki","year":"2013","journal-title":"Eur J Cancer"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2383","article-title":"Macrophage inflammatory protein 1-alpha (MIP-1\u03b1) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells","volume":"101","author":"Lentzsch","year":"2003","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-557298","article-title":"A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance","volume":"124","author":"Liu","year":"2014","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.733030","article-title":"Autocrine and paracrine interactions between multiple myeloma cells and bone marrow stromal cells by growth arrest-specific gene 6 cross-talk with interleukin-6*","volume":"292","author":"Furukawa","year":"2017","journal-title":"J Biol Chem"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01193.x","article-title":"Expression of interleukin-1\u03b2 and tumour necrosis factor-\u03b1 in plasma cells from patients with multiple myeloma","volume":"104","author":"Sati","year":"1999","journal-title":"Br J Haematol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1053-03","article-title":"Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-\u03b1 via TNF receptor 2 and autocrine up-regulation of MCP-1","volume":"10","author":"Jo\u0308hrer","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1038\/bcj.2012.37","article-title":"The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies","volume":"2","author":"Kalff","year":"2012","journal-title":"Blood Cancer J"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2907","article-title":"Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma","volume":"101","author":"Bisping","year":"2003","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2714","article-title":"FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation\u2013Induced Mitochondrial Oxidative Stress","volume":"80","author":"Ronca","year":"2020","journal-title":"Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"key":"B128","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garc\u00eda-Ortiz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B129","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2019.01063","article-title":"The role of tumor microenvironment in genomic instability of Malignant tumors","volume":"10","author":"Sonug\u00fcr","year":"2019","journal-title":"Front Genet"},{"key":"B130","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jcp.21908","article-title":"The hematopoietic stem cell niche: Low in oxygen but a nice place to be","volume":"222","author":"Eliasson","year":"2010","journal-title":"J Cell Physiol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.961637","article-title":"Role of hypoxia in the tumor microenvironment and targeted therapy","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"8995","DOI":"10.1093\/nar\/gkt671","article-title":"Oxidative stress-induced mutagenesis in single-strand DNA occurs primarily at cytosines and is DNA polymerase zeta-dependent only for adenines and guanines","volume":"41","author":"Degtyareva","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2017.04.010","article-title":"Selinexor overcomes hypoxia-induced drug resistance in multiple myeloma","volume":"10","author":"Muz","year":"2017","journal-title":"Transl Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02494-5","article-title":"Hypoxia induces chemoresistance to proteasome inhibitors through orchestrating deSUMOylation and ubiquitination of SRC-3 in multiple myeloma","volume":"41","author":"Guo","year":"2022","journal-title":"Oncogene"},{"key":"B135","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/HP.S93413","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"3","author":"Muz","year":"2015","journal-title":"Hypoxia (Auckland NZ)"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.cell.2019.04.040","article-title":"A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia","volume":"177","author":"Baryawno","year":"2019","journal-title":"Cell"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.2.487.487","article-title":"Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis","volume":"85","author":"Kawano","year":"1995","journal-title":"Blood"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1981","article-title":"Eosinophils are required for the maintenance of plasma cells in the bone marrow","volume":"12","author":"Chu","year":"2011","journal-title":"Nat Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-259457","article-title":"Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow","volume":"116","author":"Winter","year":"2010","journal-title":"Blood"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1159\/000443275","article-title":"The impact of mast cell density on the progression of bone disease in multiple myeloma patients","volume":"168","author":"Vyzoukaki","year":"2015","journal-title":"Int Arch Allergy Immunol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.coph.2020.08.006","article-title":"Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors","volume":"54","author":"Chen","year":"2020","journal-title":"Curr Opin Pharmacol"},{"key":"B142","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2013.03.002","article-title":"HGF and IGF-1 synergize with SDF-1\u03b1 in promoting migration of myeloma cells by cooperative activation of p21-activated kinase","volume":"41","author":"R\u00f8","year":"2013","journal-title":"Exp Hematol"},{"key":"B143","article-title":"Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)\u2013dependent migration and homing in multiple myeloma","volume":"109","author":"Alsayed","year":"2006","journal-title":"Blood"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2066","article-title":"Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells","volume":"103","author":"Qiang","year":"2004","journal-title":"Blood"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003704","article-title":"Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth","volume":"6","author":"Lemaitre","year":"2022","journal-title":"Blood Adv"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1852517","DOI":"10.1155\/2017\/1852517","article-title":"Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma. Giovarelli M, editor","volume":"2017","author":"Musolino","year":"2017","journal-title":"Mediators Inflamm"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B2200277","article-title":"High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma","volume":"23","author":"Yue","year":"2022","journal-title":"J Zhejiang Univ Sci B"},{"key":"B148","doi-asserted-by":"publisher","first-page":"106709","DOI":"10.1016\/j.leukres.2021.106709","article-title":"Tumor-associated macrophages modulate angiogenesis and tumor growth in a xenograft mouse model of multiple myeloma","volume":"110","author":"Sun","year":"2021","journal-title":"Leuk Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005327","article-title":"Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNF\u03b1","volume":"5","author":"Akhmetzyanova","year":"2021","journal-title":"Blood Adv"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2003","article-title":"Platelets enhance multiple myeloma progression via IL-1\u03b2 Upregulation","volume":"24","author":"Takagi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2010.04.003","article-title":"Adhesion molecules\u2014The lifelines of multiple myeloma cells","volume":"20","author":"Katz","year":"2010","journal-title":"Semin Cancer Biol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006715504719","article-title":"Significance of VLA-4\u2013VCAM-1 interaction and CD44 for transendothelial invasion in a bone marrow metastatic myeloma model","volume":"17","author":"Okada","year":"1999","journal-title":"Clin Exp Metastasis"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10849","article-title":"Microenvironment drug resistance in multiple myeloma: emerging new players","volume":"7","author":"Di Marzo","year":"2016","journal-title":"Oncotarget"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.9.3095","article-title":"Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms","volume":"85","author":"Boyd","year":"1988","journal-title":"Proc Natl Acad Sci"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0400","article-title":"Potent activity of an anti-ICAM1 antibody\u2013drug conjugate against multiple myeloma","volume":"26","author":"Sherbenou","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01762.x","article-title":"Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1","volume":"107","author":"Sanz-Rodr\u00edguez","year":"1999","journal-title":"Br J Haematol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41598-021-03748-0","article-title":"Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival","volume":"12","author":"Hathi","year":"2022","journal-title":"Sci Rep"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2839","article-title":"VLA4-targeted nanoparticles hijack cell adhesion-mediated drug resistance to target refractory myeloma cells and prolong survival","volume":"27","author":"Fontana","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0331-6","article-title":"B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src\/STAT3 and c-Cbl-mediated degradation of SOCS3","volume":"33","author":"Lin","year":"2019","journal-title":"Leukemia"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.7","article-title":"Immunomodulatory molecule PD-L1 is expressed on Malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients","volume":"5","author":"Yousef","year":"2015","journal-title":"Blood Cancer J"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.613007","article-title":"PD-L1\/PD-1 pattern of expression within the bone marrow immune microenvironment in smoldering myeloma and active multiple myeloma patients","volume":"11","author":"Costa","year":"2021","journal-title":"Front Immunol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.63","article-title":"Evolutionary biology of high-risk multiple myeloma","volume":"17","author":"Pawlyn","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02178-3","article-title":"Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma","volume":"29","author":"Larrayoz","year":"2023","journal-title":"Nat Med"},{"key":"B166","doi-asserted-by":"crossref","first-page":"2057837","DOI":"10.1080\/2162402X.2022.2057837","article-title":"Myeloma-derived IL-32\u03b3 induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis","volume":"11","author":"Liu","year":"2022","journal-title":"Oncoimmunology"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.141","article-title":"Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells","volume":"26","author":"Kim","year":"2012","journal-title":"Leukemia"},{"key":"B168","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2217\/fon-2022-0975","article-title":"A phase II multi-arm study of magrolimab combinations in patients with relapsed\/refractory multiple myeloma","volume":"19","author":"Paul","year":"2023","journal-title":"Futur Oncol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.141683","article-title":"CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma","volume":"6","author":"Lewinsky","year":"2021","journal-title":"JCI Insight"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-015-9921-z","article-title":"Interleukin-10 induces both plasma cell proliferation and angiogenesis in multiple myeloma","volume":"21","author":"Alexandrakis","year":"2015","journal-title":"Pathol Oncol Res"},{"key":"B171","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.immuni.2018.01.006","article-title":"Interleukin-10 directly inhibits CD8+ T cell function by enhancing N-glycan branching to decrease antigen sensitivity","volume":"48","author":"Smith","year":"2018","journal-title":"Immunity"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4169","article-title":"Role of transforming growth factor-beta in hematologic Malignancies","volume":"107","author":"Dong","year":"2006","journal-title":"Blood"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1059715","article-title":"Targeting TGF-\u03b2 signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction","volume":"10","author":"Rana","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1006\/cbir.2000.0497","article-title":"Role of interleukin-6 in the pathogenesis of multiple myeloma","volume":"24","author":"Gad\u00f3","year":"2000","journal-title":"Cell Biol Int"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09154.x","article-title":"Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells","volume":"158","author":"Kim","year":"2012","journal-title":"Br J Haematol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"e003975","DOI":"10.1136\/jitc-2021-003975","article-title":"Tumor-associated macrophages in multiple myeloma: advances in biology and therapy","volume":"10","author":"Sun","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B177","doi-asserted-by":"publisher","first-page":"8975","DOI":"10.3390\/curroncol29110705","article-title":"Treating multiple myeloma in the context of the bone marrow microenvironment","volume":"29","author":"Ho","year":"2022","journal-title":"Curr Oncol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"e35981","DOI":"10.1371\/journal.pone.0035981","article-title":"Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent","volume":"7","author":"Feyler","year":"2012","journal-title":"PloS One"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat Immunol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7969","article-title":"Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)","volume":"7","author":"Giallongo","year":"2016","journal-title":"Oncotarget"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1646-4","article-title":"Tumor-induced CD14+HLA-DR\u2013\/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients","volume":"64","author":"Wang","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16881","article-title":"Lenalidomide and poMalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma","volume":"191","author":"Kuwahara-Ota","year":"2020","journal-title":"Br J Haematol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-623975","article-title":"Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing","volume":"126","author":"Leone","year":"2015","journal-title":"Blood"},{"key":"B184","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0153-6","article-title":"Multiple myeloma clonal evolution in homogeneously treated patients","volume":"32","author":"Corre","year":"2018","journal-title":"Leukemia"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B187","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/cells9020287","article-title":"Prognosis, biology, and targeting of TP53 dysregulation in multiple myeloma","volume":"9","author":"Flynt","year":"2020","journal-title":"Cells"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.168872","article-title":"The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma","volume":"102","author":"Thanendrarajan","year":"2017","journal-title":"Haematologica"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000080","article-title":"Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness","volume":"134","author":"Munawar","year":"2019","journal-title":"Blood"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"B191","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1096852","article-title":"Experts\u2019 consensus on the definition and management of high risk multiple myeloma","volume":"12","author":"Marcon","year":"2023","journal-title":"Front Oncol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02227-8","article-title":"p53-NEIL1 co-abnorMalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain)","volume":"41","author":"Teoh","year":"2022","journal-title":"Oncogene"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.04.004","article-title":"Thalidomide and lenalidomide in the treatment of multiple myeloma","volume":"42","author":"Kumar","year":"2006","journal-title":"Eur J Cancer"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.217943","article-title":"IKZF1\/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma","volume":"105","author":"Barrio","year":"2020","journal-title":"Haematologica"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"B198","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/s41467-022-28515-1","article-title":"Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma","volume":"13","author":"Ng","year":"2022","journal-title":"Nat Commun"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kort\u00fcm","year":"2016","journal-title":"Blood"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0205-y","article-title":"A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity","volume":"33","author":"Liu","year":"2019","journal-title":"Leukemia"},{"key":"B201","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","article-title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma","volume":"13","author":"Vo","year":"2022","journal-title":"Nat Commun"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015909","article-title":"Loss of COP9-signalosome genes at 2q37 is associated with IMiD agent resistance in multiple myeloma","volume":"140","author":"Gooding","year":"2022","journal-title":"Blood"},{"key":"B203","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00277-018-3465-8","article-title":"Glucocorticoids in multiple myeloma: past, present, and future","volume":"98","author":"Burwick","year":"2019","journal-title":"Ann Hematol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205205","article-title":"Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays","volume":"21","author":"Chauhan","year":"2002","journal-title":"Oncogene"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.07.003","article-title":"Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells","volume":"36","author":"Tsubaki","year":"2012","journal-title":"Leuk Res"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0989-4","article-title":"Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma","volume":"35","author":"Allmeroth","year":"2021","journal-title":"Leukemia"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.088211","article-title":"Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value","volume":"99","author":"An","year":"2014","journal-title":"Haematologica"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-328252","article-title":"Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3","volume":"118","author":"Shaughnessy","year":"2011","journal-title":"Blood"},{"key":"B209","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/cancers13020256","article-title":"Gain\/Amplification of chromosome arm 1q21 in multiple myeloma","volume":"13","author":"Hanamura","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157081","article-title":"ISG20L2 suppresses bortezomib anti-myeloma activity by attenuating bortezomib binding to PSMB5","volume":"7","author":"Yang","year":"2022","journal-title":"JCI Insight"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.723016","article-title":"S100 calcium binding protein family members associate with poor patient outcome and response to proteasome inhibition in multiple myeloma","volume":"9","author":"Liu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B212","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41467-021-21386-y","article-title":"Targeting NSD2-mediated SRC-3 liquid\u2013liquid phase separation sensitizes bortezomib treatment in multiple myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): A randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"B215","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1182\/blood-2019-123483","article-title":"Four-year follow-up of the phase 3 pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus Lenalidomide and Dexamethasone (Rd) alone in Relapsed or Refractory Multiple Myeloma (RRMM)","volume":"134","author":"Kaufman","year":"2019","journal-title":"Blood"},{"key":"B216","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"B218","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1182\/blood-2021-149024","article-title":"Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (Pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of griffin after 24 months of maintenance","volume":"138","author":"Laubach","year":"2021","journal-title":"Blood"},{"key":"B219","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"B221","article-title":"Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2022","journal-title":"J Clin Oncol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"key":"B224","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better","volume":"34","author":"D\u2019Agostino","year":"2020","journal-title":"Leukemia"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0525-6","article-title":"Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7","volume":"34","author":"Kikuchi","year":"2020","journal-title":"Leukemia"},{"key":"B228","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1158\/2159-8290.CD-NB2015-169","article-title":"Multiple myeloma gets three new drugs","volume":"6","author":"Poh","year":"2016","journal-title":"Cancer Discovery"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04447-6","article-title":"Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns","volume":"100","author":"Danhof","year":"2021","journal-title":"Ann Hematol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000881","article-title":"NK cell phenotype is associated with response and resistance to daratumumab in relapsed\/refractory multiple myeloma","volume":"7","author":"Verkleij","year":"2023","journal-title":"HemaSphere"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1243997\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T17:05:04Z","timestamp":1694019904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1243997\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":233,"alternative-id":["10.3389\/fimmu.2023.1243997"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1243997","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,6]]},"article-number":"1243997"}}